IP Library Granted Patent US 9,974,815
Granted Patent B2
US 9,974,815 · App. 15/803,723 · Granted May 22, 2018

Compositions comprising bacterial strains

Inventors: Imke Elisabeth Mulder (Aberdeen, GB); Amy Beth Holt (Aberdeen, GB); Domenico Panzica (Aberdeen, GB); Seanin Marie McClusky (Aberdeen, GB)
Assignee: 4D Pharma Research Limited
A61K35/74A23C9/1585A23L33/135A61K9/19A61K31/739A61K39/09A61K45/06A23V2002/00A61K2035/11A61K2039/585
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,974,815
App. No.
15/803,723
Granted
May 22, 2018
Kind
B2
Abstract

The invention provides compositions comprising bacterial strains for treating and preventing cancer.

Claims (12)

1. A method of treatment of cancer in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition that comprises: a bacteria strain with a 16s rRNA gene sequence with at least 99.5% sequence identity to the polynucleotide of SEQ ID NO:2, wherein the sequence identity is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62; wherein said bacteria strain has a carbohydrate fermentation profile that comprises: (i) a positive fermentation of at least one of: L-arabinose and D-xylose; and (ii) an intermediate fermentation of Methyl-αD-glycopyranoside; wherein said bacteria strain is present in an amount sufficient for treatment of cancer in the subject, and wherein the cancer is a solid tumor cancer.

2. The method of claim 1 , wherein said carbohydrate profile further comprises a positive fermentation of at least one of: D-tagatose, D-ribose, potassium gluconate, D-galactose, D-glucose, D-fructose, D-mannose, N-acetylglucosamine, amygdalin, arbutin, salicin, D-cellobiose, D-maltose, sucrose, D-trehalose, and gentiobiose.

3. The method of claim 1 , wherein said carbohydrate profile further comprises an intermediate fermentation of at least one of: D-mannitol, D-lactose, and starch.

4. The method of claim 1 , wherein said carbohydrate profile further comprises:

(i) a positive fermentation of at least one of: D-tagatose, D-ribose, potassium gluconate, D-galactose, D-glucose, D-fructose, D-mannose, N-acetylglucosamine, amygdalin, arbutin, salicin, D-cellobiose, D-maltose, sucrose, D-trehalose, and gentiobiose; and

(ii) an intermediate fermentation of at least one of: D-mannitol, D-lactose, and starch.

5. The method of claim 4 , wherein said carbohydrate profile comprises a positive fermentation of L-arabinose, D-xylose, and gentiobiose.

6. The method of claim 4 , wherein said carbohydrate profile comprises a positive fermentation of L-arabinose and D-xylose and an intermediate fermentation of Methyl-αD-glycopyranoside.

7. The method of claim 1 , wherein the bacteria strain is live and viable.

8. The method of claim 1 , wherein said bacteria strain comprises the 16s rRNA gene sequence of SEQ ID NO:2.

9. The method of claim 1 , wherein said bacteria strain is of the species Enterococcus gallinarum.

10. The method of claim 1 , wherein said bacteria strain is the bacteria strain deposited under accession number NCIMB 42488.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2023
From: 4D PHARMA PLC; 4D PHARMA RESEARCH LIMITED
To: CJ BIOSCIENCE, INC.
Reel/Frame 063992/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: OXFORD FINANCE LUXEMBOURG S.A R.L.
To: ARMISTICE CAPITAL MASTER FUND LTD.
Reel/Frame 061806/0371 →
INTELECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 30, 2021
From: 4D PHARMA PLC; 4D PHARMA RESEARCH LIMITED; 4D PHARMA CORK LIMITED; 4D PHARMA DELAWARE INC.
To: OXFORD FINANCE LUXEMBOURG S.A R.L.
Reel/Frame 057042/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2018
From: MULDER, IMKE; HOLT, AMY BETH; PANZICA, DOMENICO; MCCLUSKEY, SEANIN
To: 4D PHARMA RESEARCH LIMITED
Reel/Frame 044861/0721 →
Priority Claims (2)
GB 1520502.4 · Nov 20, 2015 · national
GB 1604924.9 · Mar 23, 2016 · national
Continuity (2)
Division 15357850 · Nov 21, 2016
Related Publication 20180055892A1 · Mar 1, 2018